Biotech Values

[DewDiligence]

IDIX 2008-2009 Clinical Goals

[Update: IDX375 paper to be presented at AASLD.]


HIV

Late 2008: Start phase-2 combination study (IDX899+Truvada vs Sustiva+Truvada) in first- and second-line patients.

Late 2008: Partner IDX899 program. (Please see #msg-28959639 for musings on the terms of such a partnership). Ron Renaud said IDIX is in “advanced discussions with two different groups,” neither of which is NVS.


HCV

Nov 2008: Present first paper on IDX375 at AASLD.

Late 2008: Complete IDX184 SAD study in healthy volunteers and start 3-day monotherapy study in HCV patients.

Late 2008/early 2009: Start IDX184 phase-2a combination study (SoC ± IDX184).

April 2009: Report preliminary results of IDX184 phase-2a study at EASL.

1H09: File IND for IDX375 non-nucleoside polymerase inhibitor.

1H09: File IND for IDX136 and IDX316 protease inhibitors.